In a poster presented at the American Academy of Neurology 2023 Annual Meeting, researchers from Hartford HealthCare compared the utility of skin biopsy testing, using the Syn-One Test from CND Life Sciences, to DaTscan for diagnosing synucleinopathies.
A study published this week in NJP Parkinson’s Disease compared two methods of detecting alpha-synuclein in patients with early-stage idiopathic REM sleep behavior disorder (iRBD), a neurodegenerative disorder that often precedes the development of Parkinson’s disease and other neurodegenerative diseases.
CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, today announced topline results from its landmark Synuclein-One Study sponsored by the National Institutes of Health (NIH).
The last two weeks brought important milestones for CND Life Sciences, and several news outlets are taking notice of major developments for the company.
WJAR news reported last month about a Pawtucket, Rhode Island man, Roger Miller, who began to suffer from shaky movements about 10 years ago.
Company Focuses on Innovative Diagnosis and Treatment of Neurodegenerative Diseases
Agreement with Beth Israel Deaconess Medical Center Solidifies Important Technology for CND’s Syn-One Test® and Creates Opportunity for Future Innovations in the Field
Research published last month in the New England Journal of Medicine demonstrated that a focused ultrasound procedure improved motor function in patients with Parkinson’s disease.
San Diego-based Ryne Biotechnology announced last week that it has received a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM) to move RNDP-0001 into clinical testing.